High Level of Adherence to Alirocumab and Concomitant Background Treatments for Patients With Heterozygous Familial Hypercholesterolemia in the ODYSSEY Open-Label Extension Study

被引：0
|
作者：
Farnier, Michel A.
Hovingh, G. Kees
Langslet, Gisle
Dufour, Robert
Baccara-Dinet, Marie T.
Din-Bell, Chantal
Manvelian, Garen
Guyton, John R.
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
PCSK9; Adherence; Cholesterol-lowering drugs; Hyperlipidemia; LDL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15057
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies
    Raal, Frederick J.
    Hegele, Robert A.
    Ruzza, Andrea
    Lopez, J. Antonio G.
    Bhatia, Ajay K.
    Wu, Johnny
    Wang, Huei
    Gaudet, Daniel
    Wiegman, Albert
    Wang, Jian
    Santos, Raul D.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2024, 44 (05) : 1156 - 1164
  • [42] EVOLOCUMAB TREATMENT IN PAEDIATRIC PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: DATA FROM THREE POOLED OPEN-LABEL STUDIES
    Raal, F.
    Ruzza, A.
    Opez, J. A. L.
    Bhatia, A.
    Wu, J.
    Wang, H.
    Gaudet, D.
    Wiegman, A.
    Hegele, R.
    Santos, R.
    ATHEROSCLEROSIS, 2023, 379
  • [43] Efficacy and Safety of Lerodalcibep, a Third Generation PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial
    Raal, Frederick
    Fourie, Nyda
    Scott, Russell
    Blom, Dirk
    Kayikcioglu, Meral
    Vest, Jeff
    Kallend, David
    Stein, Evan
    CIRCULATION, 2024, 150 (25) : E730 - E731
  • [44] A SIX-MONTH OPEN-LABEL EXTENSION STUDY OF VORTIOXETINE IN PEDIATRIC PATIENTS
    Findling, Robert L.
    Robb, Adelaide S.
    DelBello, Melissa P.
    Huss, Michael
    McNamara, Nora K.
    Sarkis, Elias H.
    Scheffer, Russell E.
    Poulsen, Lis H.
    Chen, Grace
    Lemming, Ole M.
    Auby, Philippe
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2016, 55 (10): : S183 - S183
  • [45] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RHEUMATOID ARTHRITIS PATIENTS
    Genovese, Mark C.
    Fay, Jon
    Parrino, Janie
    Beyer, Doris
    Iglesias-Rodriguez, Melitza
    Graham, Neil
    Boddy, Alex
    Martincova, Renata
    Burmester, Gerd R.
    RHEUMATOLOGY, 2017, 56 : 139 - 139
  • [46] Phase 2 Open-Label Extension Study of Patisiran, an RNAi Therapeutic for the Treatment of Familial Amyloidotic Polyneuropathy
    Adams, David
    Suhr, Ole
    Coelho, Teresa
    Conceicao, Isabel
    Waddington-Cruz, Marcia
    Schmidt, Hartmut
    Buades, Juan
    Campistol, Josep
    Pouget, Jean
    Berk, John
    Falzone, Rick
    Harrop, Jamie
    De Frutos, Ricardo
    Bettencourt, Brian
    Cehelsky, Jeffrey
    Nochur, Sara
    Vaishnaw, Akshay
    Gollob, Jared
    ANNALS OF NEUROLOGY, 2014, 76 : S113 - S113
  • [47] Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study
    Feagan, Brian G.
    Panes, Julian
    Ferrante, Marc
    Kaser, Arthur
    D'Haens, Geert R.
    Sandborn, William J.
    Louis, Edouard
    Neurath, Markus F.
    Franchimont, Denis
    Dewit, Olivier
    Seidler, Ursula
    Kim, Kyung-Jo
    Selinger, Christian
    Padula, Steven J.
    Herichova, Ivona
    Robinson, Anne M.
    Wallace, Kori
    Zhao, Jun
    Minocha, Mukul
    Othman, Ahmed A.
    Soaita, Adina
    Visvanathan, Sudha
    Hall, David B.
    Boecher, Wulf O.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (10): : 671 - 680
  • [48] OPEN-LABEL EXTENSION STUDY: TEZACAFTOR/IVACAFTOR, PATIENTS ≥ 12 YEARS WITH CYSTIC FIBROSIS
    Wainwright, C.
    Flume, P.
    Biner, Fischer R.
    Downey, D.
    Brown, C.
    Jain, M.
    Fischer, R.
    De Boeck, K.
    Campbell, D.
    Wang, X.
    Ahluwalia, N.
    Owen, C.
    RESPIROLOGY, 2020, 25 : 57 - 57
  • [49] PHASE 2 OPEN-LABEL EXTENSION STUDY WITH DONIDALORSEN TREATMENT IN PATIENTS WITH HEREDITARY ANGIOEDEMA
    Bordone, L.
    Riedl, M.
    Newman, K.
    Lui, C.
    Alexander, V.
    Schneider, E.
    Cohn, D.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S33 - S33
  • [50] An open-label extension study of lurasidone in patients with schizophrenia previously randomized to lurasidone or risperidone
    Mattingly, G.
    Tocco, M.
    Cucchiaro, J.
    Xu, J.
    Pikalov, A.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S559 - S559
12345